In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

@article{PilotMatias2015InVA,
  title={In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.},
  author={Tami J. Pilot-Matias and Rakesh L Tripathi and Daniel E. Cohen and Isabelle A Gaultier and Tatyana Dekhtyar and Liangjun Lu and Thomas J Reisch and Michelle Irvin and Todd A. Hopkins and Ron B. Pithawalla and Timothy Middleton and Teresa I. Ng and Keith F McDaniel and Yat Sun Or and Rajeev M. Menon and Dale J. Kempf and Akhteruzzaman Molla and Christine N. Collins},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 2},
  pages={988-97}
}
The development of direct-acting antiviral agents is a promising therapeutic advance in the treatment of hepatitis C virus (HCV) infection. However, rapid emergence of drug resistance can limit efficacy and lead to cross-resistance among members of the same drug class. ABT-450 is an efficacious inhibitor of HCV NS3/4A protease, with 50% effective concentration values of 1.0, 0.21, 5.3, 19, 0.09, and 0.69 nM against stable HCV replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and 6a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

ABT - 450 / ritonavir  ombitasvir  dasabuvir : drug interactions mediated by transporters

  • R Menon
  • 2014

Similar Papers

Loading similar papers…